- Home
- FCEL vs SPRO Comparison
FCEL vs SPRO Comparison
Compare FCEL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- SPRO
- Stock Information
- Founded
- FCEL 1969
- SPRO 2013
- Country
- FCEL United States
- SPRO United States
- Employees
- FCEL N/A
- SPRO N/A
- Industry
- FCEL Industrial Machinery/Components
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- FCEL Energy
- SPRO Health Care
- Exchange
- FCEL Nasdaq
- SPRO Nasdaq
- Market Cap
- FCEL 106.2M
- SPRO 121.0M
- IPO Year
- FCEL 1992
- SPRO 2017
- Fundamental
- Price
- FCEL $5.18
- SPRO $1.98
- Analyst Decision
- FCEL Hold
- SPRO Buy
- Analyst Count
- FCEL 5
- SPRO 4
- Target Price
- FCEL $9.43
- SPRO $5.00
- AVG Volume (30 Days)
- FCEL 1.8M
- SPRO 533.5K
- Earning Date
- FCEL 09-09-2025
- SPRO 08-12-2025
- Dividend Yield
- FCEL N/A
- SPRO N/A
- EPS Growth
- FCEL N/A
- SPRO N/A
- EPS
- FCEL N/A
- SPRO N/A
- Revenue
- FCEL $152,472,000.00
- SPRO $48,576,000.00
- Revenue This Year
- FCEL $40.32
- SPRO N/A
- Revenue Next Year
- FCEL $36.17
- SPRO N/A
- P/E Ratio
- FCEL N/A
- SPRO N/A
- Revenue Growth
- FCEL 78.81
- SPRO N/A
- 52 Week Low
- FCEL $3.58
- SPRO $0.51
- 52 Week High
- FCEL $16.10
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- FCEL 66.21
- SPRO 43.66
- Support Level
- FCEL $3.93
- SPRO $1.86
- Resistance Level
- FCEL $4.53
- SPRO $2.18
- Average True Range (ATR)
- FCEL 0.28
- SPRO 0.10
- MACD
- FCEL 0.11
- SPRO 0.03
- Stochastic Oscillator
- FCEL 90.91
- SPRO 45.57
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.